FGF21 and metabolic dysfunction-associated steatotic liver disease: Taken together, these results strongly suggest that the circulating FGF21 level may reflect the severity of hepatic steatosis and may indicate the early onset of NAFLD progression, thus representing a candidate biomarker of metabolic disorders [12,180].